Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : EPD Biotherapeutics
Deal Size : Undisclosed
Deal Type : Merger
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline
Details : Through this merger, Genexine will secured key talent with innovative technology that can lead the global market and innovative new drugs based on combining EPD Bio’s bioPROTAC technology.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : EPD Biotherapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Efepoetin Alfa
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Kalbe Genexine Biologics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patien...
Brand Name : Efesa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 23, 2023
Lead Product(s) : Efepoetin Alfa
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Kalbe Genexine Biologics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Eftansomatropin Alfa
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : I-Mab Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Genexine’s long-acting growth hormone meets Phase 3 primary endpoint
Details : Genexine’s, GX-H9, a proprietary long-acting growth hormone shows positive topline results from phase 3 study for growth hormone deficiency, is being conducted in China with I-Mab.
Brand Name : GX-H9
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2023
Lead Product(s) : Eftansomatropin Alfa
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : I-Mab Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GX-188E,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GX-188E (tirvalimogene teraplasmid), a DNA vaccine encoding both E6 and E7 antigens of HPV types 16 and 18, which are responsible for about 70% of cervical cancer. It induces antigen-specific CD8 T cell responses by Flt3L fusion.
Brand Name : GX-188E
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 20, 2023
Lead Product(s) : GX-188E,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GX-188E,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GX-188E is a DNA vaccine that encodes the E6/E7 fusion protein of HPV subtypes 16 and 18. Drug induces immune cells to detect E6 and E7 proteins that exist in cervical cancer cells, inducing apoptosis of tumor cells without affecting healthy cells.
Brand Name : GX-188E
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 08, 2023
Lead Product(s) : GX-188E,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GX-188E,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : MSD Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GX-188E is a DNA-based therapeutic vaccine that was discovered and is being developed by Genexine for the treatment of cervical cancer and squamous cell carcinoma of the head and neck.
Brand Name : GX-188E
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 25, 2022
Lead Product(s) : GX-188E,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : MSD Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Efineptakin Alfa,Pembrolizumab,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results indicated that GX-I7 (Efineptakin Alfa) in combination with pembrolizumab was safe and well tolerated and demonstrated promising early anti-tumor activity in patients with R/R metastatic TNBC.
Brand Name : GX-I7
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 07, 2022
Lead Product(s) : Efineptakin Alfa,Pembrolizumab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Hanmi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi
Details : Genexine 's GX-19N COVID-19 vaccine candidate is a DNA based vaccine and showed no severe side effects. Hanmi will begin producing 10M doses of Genexine’s experimental COVID-19 vaccine with an aim to gradually ramp up production capacity to millions of...
Brand Name : GX-19N
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 18, 2021
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Hanmi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Institut Pasteur Korea
Deal Size : Undisclosed
Deal Type : Collaboration
Institut Pasteur Korea & Genexine Sign MOU for Global Clinical Trials for the COVID-19 Vaccine
Details : IPK and Genexine will join forces together to test the protective efficacy of the GX-19N in the regions such as South Africa, where variants mainly appear, utilizing the international collaboration network of Institut Pasteur Korea.
Brand Name : GX-19N
Molecule Type : Vaccine
Upfront Cash : Undisclosed
April 12, 2021
Lead Product(s) : GX-19N
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Institut Pasteur Korea
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Efineptakin alfa
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Kalbe Genexine Biologics
Deal Size : $1,100.0 million
Deal Type : Licensing Agreement
KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17
Details : Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.
Brand Name : GX-I7
Molecule Type : Large molecule
Upfront Cash : $27.0 million
February 18, 2021
Lead Product(s) : Efineptakin alfa
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Kalbe Genexine Biologics
Deal Size : $1,100.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?